Format

Send to

Choose Destination
Drug Discov Today. 2016 Sep;21(9):1429-1436. doi: 10.1016/j.drudis.2016.04.015. Epub 2016 Apr 28.

Engineered miniaturized models of musculoskeletal diseases.

Author information

1
Cell and Tissue Engineering Lab, IRCCS Istituto Ortopedico Galeazzi, Milano, Italy.
2
Department of Surgery and Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
3
Cell and Tissue Engineering Lab, IRCCS Istituto Ortopedico Galeazzi, Milano, Italy; Regenerative Medicine Technologies Lab, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; Swiss Institute for Regenerative Medicine, Lugano, Switzerland; Fondazione Cardiocentro Ticino, Lugano, Switzerland. Electronic address: matteo.moretti@grupposandonato.it.

Abstract

The musculoskeletal system is an incredible machine that protects, supports and moves the human body. However, several diseases can limit its functionality, compromising patient quality of life. Designing novel pathological models would help to clarify the mechanisms driving such diseases, identify new biomarkers and screen potential drug candidates. Miniaturized models in particular can mimic the structure and function of basic tissue units within highly controlled microenvironments, overcoming the limitations of traditional macroscale models and complementing animal studies, which despite being closer to the in vivo situation, are affected by species-specific differences. Here, we discuss the miniaturized models engineered over the past few years to analyze osteochondral and skeletal muscle pathologies, demonstrating how the rationale design of novel systems could provide key insights into the pathological mechanisms behind diseases of the musculoskeletal system.

PMID:
27132520
DOI:
10.1016/j.drudis.2016.04.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center